MARKET

ADVM

ADVM

Adverum Biotech
NASDAQ
6.44
-0.15
-2.28%
Opening 10:58 06/20 EDT
OPEN
6.57
PREV CLOSE
6.59
HIGH
6.72
LOW
6.44
VOLUME
50.72K
TURNOVER
0
52 WEEK HIGH
29.70
52 WEEK LOW
6.44
MARKET CAP
133.67M
P/E (TTM)
-0.6295
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at ADVM last week (0610-0614)?
Weekly Report · 3d ago
Adverum Biotechnologies Announces Leadership Team Changes
TipRanks · 06/11 21:01
ADVERUM BIOTECHNOLOGIES ANNOUNCES APPOINTMENTS OF DR. RABIA GURSES OZDEN AS CHIEF MEDICAL OFFICER AND DR. SZILÁRD KISS AS A MEMBER OF THE BOARD OF DIRECTORS
Reuters · 06/11 12:00
Press Release: Adverum Biotechnologies Announces Appointments of Dr. Rabia Gurses Ozden as Chief Medical Officer and Dr. Szilárd Kiss as a Member of the Board of Directors
Dow Jones · 06/11 12:00
Weekly Report: what happened at ADVM last week (0603-0607)?
Weekly Report · 06/10 09:47
Weekly Report: what happened at ADVM last week (0527-0531)?
Weekly Report · 06/03 09:48
Weekly Report: what happened at ADVM last week (0520-0524)?
Weekly Report · 05/27 09:49
Weekly Report: what happened at ADVM last week (0513-0517)?
Weekly Report · 05/20 09:47
More
About ADVM
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company. The Company discovers and develops gene therapy product candidates that provides durable efficacy by inducing sustained expression of a therapeutic protein. Its lead product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable levels of aflibercept associated with a sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) IVT injections. Ixo-vec is being developed for the treatment of patients with wet age-related macular degeneration. Its second product candidate, ADVM-062 (AAV.7m8-L-opsin), is a gene therapy product candidate being developed to treat patients suffering from blue cone monochromacy (BCM) via a single IVT injection. It also developing an early-stage pipeline of gene therapy programs.

Webull offers Adverum Biotechnologies Inc stock information, including NASDAQ: ADVM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADVM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ADVM stock methods without spending real money on the virtual paper trading platform.